Abstract:>90% of genes in the human body undergo alternative splicing (AS) after transcription, which enriches protein species and regulates protein levels. However, there is growing evidence that various genetic isoforms resulting from dysregulated alternative splicing are prevalent in various types of cancers. Dysregulated alternative splicing leads to cancer generation and maintenance of cancer properties such as proliferation differentiation, apoptosis inhibition, invasion metastasis, and angiogenesis. Serine/arginine-rich proteins and SR protein-associated kinases mediate splice site recognition and splice complex assembly during variable splicing. Based on the impact of dysregulated alternative splicing on disease onset and progression, the search for small molecule inhibitors targeting alternative splicing is imminent. In this review, we discuss the structure and specific biological functions of SR proteins and describe the regulation of SR protein function by SR protein related kinases meticulously, which are closely related to the occurrence and development of various types of cancers. On this basis, we summarize the reported small molecule inhibitors targeting SR proteins and SR protein related kinases from the perspective of medicinal chemistry. We mainly categorize small molecule inhibitors from four aspects, including targeting SR proteins, targeting Serine/arginine-rich protein-specific kinases (SRPKs), targeting Cdc2-like kinases (CLKs) and targeting dual-specificity tyrosine-regulated kinases (DYRKs), in terms of structure, inhibition target, specific mechanism of action, biological activity, and applicable diseases. With this review, we are expected to provide a timely summary of recent advances in alternative splicing regulated by kinases and a preliminary introduction to relevant small molecule inhibitors.

SR Splicing Factors Promote Cancer Via Multiple Regulatory Mechanisms.

SR proteins in cancer: function, regulation, and small inhibitor

Targeting Serine- and Arginine-Rich Splicing Factors to Rectify Aberrant Alternative Splicing.

Towards Understandings of Serine/arginine-Rich Splicing Factors

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

RNA splicing dysregulation and the hallmarks of cancer

Targeting Splicing Factor SRSF6 for Cancer Therapy

Biological Function and Molecular Mechanism of SRSF3 in Cancer and Beyond (Review)

Emerging Roles of SRSF3 As a Therapeutic Target for Cancer

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

Oncogenic SRSF3 in Health and Diseases.

A Critical Update on the Strategies Towards Small Molecule Inhibitors Targeting Serine/arginine-rich (SR) Proteins and Serine/arginine-rich Proteins Related Kinases in Alternative Splicing

Dysregulation and therapeutic targeting of RNA splicing in cancer

Small Protein Hidden in Lncrna LOC90024 Promotes “cancerous” RNA Splicing and Tumorigenesis

Splicing Dysregulation in Cancer: from Mechanistic Understanding to a New Class of Therapeutic Targets

Alternative splicing and cancer: a systematic review

Emerging Roles of Spliceosome in Cancer and Immunity

SRSF1 Prevents DNA Damage and Promotes Tumorigenesis Through Regulation of DBF4B Pre-mRNA Splicing.

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells